Substance use in youth with bipolar disorder

Author(s):  
Timothy E Wilens ◽  
Courtney A Zulauf
2008 ◽  
Author(s):  
Edwin Shirley ◽  
Lisa Stines Doane ◽  
Toyomi Goto ◽  
Norah Feeny ◽  
Sara M. Debanne ◽  
...  

2007 ◽  
Vol 62 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Timothy E. Wilens ◽  
Joseph Biederman ◽  
Joel Adamson ◽  
Michael Monuteaux ◽  
Aude Henin ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
William Moot ◽  
Marie Crowe ◽  
Maree Inder ◽  
Kate Eggleston ◽  
Christopher Frampton ◽  
...  

Objectives: Research suggests that patients with co-morbid bipolar disorder (BD) and substance use disorder (SUD) have a poorer illness course and clinical outcome. The evidence is limited as SUD patients are often excluded from BD studies. In particular, evidence regarding long term outcomes from studies using psychotherapies as an adjunctive treatment is limited. We therefore examined data from two studies of Interpersonal Social Rhythm Therapy (IPSRT) for BD to determine whether lifetime or current SUD affected outcomes.Methods: Data were analyzed from two previous clinical trials of IPSRT for BD patients. Change in scores on the Social Adjustment Scale (SAS) from 0 to 78 weeks and cumulative mood scores from 0 to 78 weeks, measured using the Life Interval Follow-Up Evaluation (LIFE), were analyzed.Results: Of 122 patients (non-SUD n = 67, lifetime SUD but no current n = 43, current SUD n = 12), 79 received IPSRT and 43 received a comparison therapy—specialist supportive care—over 18 months. Lifetime SUD had a significant negative effect on change in SAS score but not LIFE score. There was no effect of current SUD on either change in score. Secondary analysis showed no correlation between symptom count and change in SAS total score or LIFE score.Conclusion: Current SUD has no impact on mood or functional outcomes, however, current SUD numbers were small, limiting conclusions. Lifetime SUD appears to be associated with impaired functional outcomes from psychotherapy. There is limited research on co-morbid BD and SUD patients undergoing psychotherapy.


2021 ◽  
Vol 12 ◽  
Author(s):  
Vanessa Le ◽  
Dylan E. Kirsch ◽  
Valeria Tretyak ◽  
Wade Weber ◽  
Stephen M. Strakowski ◽  
...  

Background: Psychosocial stress negatively affects the clinical course of bipolar disorder. Studies primarily focused on adults with bipolar disorder suggest the impact of stress is progressive, i.e., stress response sensitizes with age. Neural mechanisms underlying stress sensitization are unknown. As stress-related mechanisms contribute to alcohol/substance use disorders, variation in stress response in youth with bipolar disorder may contribute to development of co-occurring alcohol/substance use disorders. This study investigated relations between psychosocial stress, amygdala reactivity, and alcohol and cannabis use in youth with bipolar disorder, compared to typically developing youth.Methods: Forty-two adolescents/young adults [19 with bipolar disorder, 23 typically developing, 71% female, agemean ± SD = 21 ± 2 years] completed the Perceived Stress Scale (PSS), Daily Drinking Questionnaire modified for heaviest drinking week, and a modified Montreal Imaging Stress functional MRI Task. Amygdala activation was measured for both the control and stress conditions. Main effects of group, condition, total PSS, and their interactions on amygdala activation were modeled. Relationships between amygdala response to acute stress with recent alcohol/cannabis use were investigated.Results: Greater perceived stress related to increased right amygdala activation in response to the stress, compared to control, condition in bipolar disorder, but not in typically developing youth (group × condition × PSS interaction, p = 0.02). Greater amygdala reactivity to acute stress correlated with greater quantity and frequency of alcohol use and frequency of cannabis use in bipolar disorder.Conclusion: Recent perceived stress is associated with changes in amygdala activation during acute stress with amygdala reactivity related to alcohol/cannabis use in youth with bipolar disorder.


Author(s):  
TIMOTHY E. WILENS ◽  
JOSEPH BIEDERMAN ◽  
RACHAEL B. MILLSTEIN ◽  
JANET WOZNIAK ◽  
AMY L. HAHESY ◽  
...  

2020 ◽  
pp. 75-82
Author(s):  
Josh E. Becker ◽  
E. Sherwood Brown

Bipolar disorder and substance use disorder co-occur at very high rates. The high rate is likely due to a complex interaction of biological, social, and psychological factors, and some research suggests that use of substances may be to mitigate symptoms associated with bipolar disorder. Some studies have shown that men with bipolar disorder may be at a higher risk for a substance use disorder than women. The co-occurrence of these disorders leads to poorer treatment outcomes because of higher rates of suicidality, poor treatment adherence, lower quality of life, and more frequent relapse. This population deserves special treatment consideration.


2005 ◽  
Vol 66 (06) ◽  
pp. 730-735 ◽  
Author(s):  
Roger D. Weiss ◽  
Michael J. Ostacher ◽  
Michael W. Otto ◽  
Joseph R. Calabrese ◽  
Mark Fossey ◽  
...  

1998 ◽  
Vol 59 (4) ◽  
pp. 172-174 ◽  
Author(s):  
Roger D. Weiss ◽  
Shelly F. Greenfield ◽  
Lisa M. Najavits ◽  
Jose A. Soto ◽  
Dana Wyner ◽  
...  

2019 ◽  
Vol 256 ◽  
pp. 348-357
Author(s):  
R. Icick ◽  
I. Melle ◽  
B. Etain ◽  
P.A. Ringen ◽  
S.R. Aminoff ◽  
...  

2016 ◽  
Vol 7 (2) ◽  
pp. 67-77 ◽  
Author(s):  
Sergio De Filippis ◽  
Ilaria Cuomo ◽  
Georgios D. Kotzalidis ◽  
Daniela Pucci ◽  
Pietro Zingaretti ◽  
...  

Background: Asenapine is a second-generation antipsychotic approved in Europe for treating moderate-to-severe manic episodes in adults affected by type I bipolar disorder (BD-I). We aimed to compare its efficacy in psychiatric inpatients with BD-I, with or without substance use disorder (SUD). Methods: We administered flexible asenapine doses ranging from 5–20 mg/day to 119 voluntarily hospitalized patients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) BD-I diagnosis, with or without SUD. Patients were assessed with clinician-rated questionnaires [i.e. Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), and Global Assessment of Functioning (GAF)]. Assessments were carried out at baseline (T0, prior to treatment), and 3 (T1), 7 (T2), 15 (T3), and 30 days (T4) after starting treatment for all clinical scales and at T0 and T4 for the GAF. Results: Patients improved on all scales ( p < 0.001) across all timepoints, as shown both by paired-sample comparisons and by applying a repeated-measures, generalized linear model (GLM). Patients without comorbid SUD showed greater reductions in BPRS scores at T2 and T3, greater reduction in YMRS scores at T3, and lower HARS scores at all timepoints. HDRS scores did not differ between the two groups at any timepoint. However, the reduction in HARS scores in the comorbid group was stronger than in the BD-I only group, albeit not significantly. Side effects were few and mild-to-moderate. Conclusions: The open-label design and the relatively short observation period may expose to both type I and type II statistical errors (false positive and false negatives). Asenapine showed effectiveness and safety in hospitalized BD-I patients. Its effect was stronger in patients without comorbid SUD.


Sign in / Sign up

Export Citation Format

Share Document